Key result
Early dual antiplatelet therapy with clopidogrel and aspirin reduced the 1-year risk of stroke compared to aspirin alone (10.6% vs 14.0%; HR 0.78) in patients with minor stroke or TIA.
Why the study?
Does dual antiplatelet therapy (aspirin and clopidogrel) prevent recurrent ischemic events without increasing bleeding risk in patients with acute ischemic stroke or TIA?
Does dual antiplatelet therapy (aspirin and clopidogrel) prevent recurrent ischemic events without increasing bleeding risk in patients with acute ischemic stroke or TIA?
Hazard Ratio: 0.78 (95% CI 0.65–0.93)
Absolute Event Rate: 10.6% vs 14%
p-value: p=0.006
While dual antiplatelet therapy is beneficial in acute coronary syndromes, its use in the acute phase of ischemic stroke or TIA is associated with an increased risk of major bleeding.
Patients with stroke or transient ischemic attack (TIA) are at high risk of recurrence. Approximately 10-20% of patients have another stroke within the first 3 months of the index event. Recurrent strokes can be disabling for patients, sometimes resulting in fatal consequences. The role of aspirin has been established in the acute phase as well as in secondary prevention of future ischemic strokes. Clopidogrel, an inhibitor of adenosine diphosphate (ADP) receptor on platelet cell membranes, along with aspirin synergistically prevents platelet activation and further ischemic events. Beneficial effects of this dual antiplatelet therapy (DAPT) in acute coronary syndromes have been established, without any increased risk of bleeding, however the same cannot be said about secondary prevention of stroke. In the acute phase, ischemic strokes are prone to hemorrhagic transformation spontaneously and a recently published meta-analysis of five randomized controlled trials, which enrolled patients with acute ischemic stroke or TIA, reported an increase in major bleeding with the combination therapy.
No takes yet. Share an insight, caveat, or question.
Brandler et al. (2015) conducted an editorial in Minor stroke or transient ischemic attack (TIA) (n=5,170). Dual antiplatelet therapy (clopidogrel and aspirin) vs. 75 mg aspirin for 90 days alone was evaluated on Stroke (ischemic or hemorrhagic) during the 1-year follow-up (HR 0.78, 95% CI 0.65-0.93, p=0.006). Early dual antiplatelet therapy with clopidogrel and aspirin reduced the 1-year risk of stroke compared to aspirin alone (10.6% vs 14.0%; HR 0.78) in patients with minor stroke or TIA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: